Reliance-backed Strand Life Sciences has received an Indian patent for an AI-powered blood test designed for early-stage cancer detection. The technology uses genome sequencing and machine learning to identify cancer through simple blood samples, potentially improving screening accessibility in India.
Strand Life Sciences, a genomic research company where Reliance Industries holds a majority stake, has secured an Indian patent for its artificial intelligence-based technology designed to detect cancer at an early stage. The platform uses a process often referred to as liquid biopsy, which analyzes cell-free DNA from blood samples to identify markers of the disease.
Technology Behind the Patent
The patented method, developed at the company's Bengaluru facility, integrates multiple complex biological processes including genome sequencing, methylation profiling, and fragmentomics. By applying machine learning to these data points, the platform can detect the presence of cancer and predict the origin of the tumor. This approach is intended to provide a less invasive alternative to traditional biopsy methods, which often require surgery or tissue extraction.
For the Indian healthcare market, this innovation addresses a critical need. India sees over 1.5 million new cancer cases every year, many of which are identified only at later stages when treatment options are limited and costs are significantly higher. The company indicated that as the cost of genome sequencing continues to fall, this technology could be deployed on a larger scale, potentially overcoming the lack of specialized infrastructure in many parts of the country.
Strategic Importance for Strand Life Sciences
Securing this patent strengthens the intellectual property portfolio of Strand Life Sciences, which originated as a spin-off from the Indian Institute of Science. The company has been building an integrated suite of AI-enabled molecular diagnostics to support both clinical early detection and precision oncology, which involves tailoring treatment plans based on a patient's genetic profile.
While this patent is a technical milestone, the path to commercial success will depend on factors like clinical adoption, regulatory clearance for specific diagnostic applications, and how effectively the company can price these tests to compete with established diagnostic chains. Strand Life Sciences has been expanding its multi-omics capabilities to support pharmaceutical research and drug development, which serves as a secondary revenue stream alongside its clinical diagnostic services.
Investors should note that the diagnostic and genomic testing sector is highly competitive, with both global players and large domestic laboratory chains vying for market share. A key monitorable for the company will be its ability to translate this patented intellectual property into a scalable commercial product that healthcare providers and hospitals are willing to adopt for routine screenings.